Theralase Technologies Inc. V.TLT

Big pharmas are watching us closely!

[Lesalpes29]

Fir sure : https://www.fiercebiotech.com/biotech/ma-down-big-pharma-likely-line-multiple-shots-goal-heading-2nd-half

[Lesalpes29]

For sure! Of course!

[gojotv!]

Agreed. In fact, I believe that Big Pharmas have agents on this board trying to convince shareholders to sell to them cheap. There's something called an "anchoring bias" where a buyer will start the bidding at a ridiculously low number to keep the ultimate selling price down. I've seen that a lot on these boards, with pundits talking about a fast sell-out as soon as clear

[ScienceFirst]

Ask yourself if the acquisitions were able to destroy late-stage solid tumors?  The answer is no. Then, add this ability to do it with only a 2-doses treatment, with no side effects, all this with a standalone   treatment that doesn't need adjuvants.  Then, fix your valuation, to better assess the magnitude of the task.   Bristol Myers Squibb’s $4 billion

[ScienceFirst]

Imagine the upfront $$$ to access to our technology. If we're to become a future SOC, our Ph. 2 data will be valued extremely high, when you see a perspective like below, as our first successful indication would di facto confirm the huge potential of our ACT platform. GSK has responded by inking a deal to buy privately held Affinivax for $2.1 billion upfront and two $600 million

[ScienceFirst]

  There were some interesting deals in the half, particularly Pfizer’s $11.6 billion check for a chunk of Biohaven Pharmaceuticals. The New York Big Pharma carved out Biohaven’s migraine franchise while leaving some earlier-stage assets under the biotech’s purview.

[Legit62]

SF, if we get good news on Vaccine front, it will really add to our value, besides the fact that we destroy tumors, safely, cost efficient, and minimal treatments compared to rivals

[Eoganacht]

Theralase's treatment destroys tumours completely, and that safely...how many anti-cancer drugs only shrink tumours at best? TLD1433 pdt should be a useful addition to most anti-cancer regimens to get the situation under control. What is a treatment like that worth? Should we just add up the cancer indications it's good for and multiply by a few billion?